Do analysts recommend SEER or OPTX?

Seer presently has a consensus price target of $4.00, suggesting a potential upside of 103.05%. Given Seer's stronger consensus rating and higher possible upside, equities analysts clearly believe Seer is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seer 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00 Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, SEER or OPTX?

Syntec Optics has higher revenue and earnings than Seer. Syntec Optics is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seer $14.68M 7.38 -$73.60M -$1.24 N/A Syntec Optics $27.53M 10.32 -$1.79M -$0.08 N/A

Is SEER or OPTX more profitable?

Syntec Optics has a net margin of -10.95% compared to Seer's net margin of -464.78%. Seer's return on equity of -26.58% beat Syntec Optics' return on equity. Company Net Margins Return on Equity Return on Assets Seer -464.78% -26.58% -23.51% Syntec Optics -10.95% -30.86% -12.35%

Does the media favor SEER or OPTX?

In the previous week, Seer had 9 more articles in the media than Syntec Optics. MarketBeat recorded 14 mentions for Seer and 5 mentions for Syntec Optics. Syntec Optics' average media sentiment score of 0.92 beat Seer's score of 0.34 indicating that Syntec Optics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seer 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Syntec Optics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SEER or LAB more profitable?

Standard BioTools has a net margin of 73.46% compared to Seer's net margin of -464.78%. Standard BioTools' return on equity of -8.18% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets Seer -464.78% -26.58% -23.51% Standard BioTools 73.46% -8.18% -6.43%

Does the media refer more to SEER or LAB?

In the previous week, Seer had 6 more articles in the media than Standard BioTools. MarketBeat recorded 14 mentions for Seer and 8 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.83 beat Seer's score of 0.34 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seer 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Standard BioTools 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SEER or PRE?

Prenetics Global has higher revenue and earnings than Seer. Prenetics Global is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seer $14.68M 7.38 -$73.60M -$1.24 N/A Prenetics Global $120.07M 2.63 -$37.71M -$4.58 N/A

Is SEER or PRE more profitable?

Prenetics Global has a net margin of -62.45% compared to Seer's net margin of -464.78%. Prenetics Global's return on equity of -20.33% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets Seer -464.78% -26.58% -23.51% Prenetics Global -62.45% -20.33% -15.42%

Does the media prefer SEER or PRE?

In the previous week, Seer had 9 more articles in the media than Prenetics Global. MarketBeat recorded 14 mentions for Seer and 5 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.41 beat Seer's score of 0.34 indicating that Prenetics Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seer 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Prenetics Global 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, MASS or SEER?

908 Devices has higher revenue and earnings than Seer. 908 Devices is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 908 Devices $57.80M 4.67 $19.49M -$1.00 N/A Seer $14.68M 7.38 -$73.60M -$1.24 N/A

Is MASS or SEER more profitable?

908 Devices has a net margin of -62.40% compared to Seer's net margin of -464.78%. 908 Devices' return on equity of -14.03% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets 908 Devices -62.40% -14.03% -10.40% Seer -464.78% -26.58% -23.51%

Does the media refer more to NAUT or SEER?

In the previous week, Seer had 11 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 14 mentions for Seer and 3 mentions for Nautilus Biotechnology. Seer's average media sentiment score of 0.34 beat Nautilus Biotechnology's score of 0.29 indicating that Seer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seer 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Seer (SEER) Competitors

$1.97 -0.08 (-3.90%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.98 +0.01 (+0.25%)

As of 07/24/2026 07:34 PM Eastern

Compare

SEER vs. OPTX, LAB, PRE, MASS, and NAUT

Should you buy Seer stock or one of its competitors? MarketBeat compares Seer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Seer include Syntec Optics (OPTX), Standard BioTools (LAB), Prenetics Global (PRE), 908 Devices (MASS), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.

How does Seer compare to Syntec Optics?

Seer (NASDAQ:SEER) and Syntec Optics (NASDAQ:OPTX) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

75.2% of Seer shares are owned by institutional investors. 11.3% of Seer shares are owned by company insiders. Comparatively, 0.8% of Syntec Optics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Syntec Optics has higher revenue and earnings than Seer. Syntec Optics is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$14.68M	7.38	-$73.60M	-$1.24	N/A
Syntec Optics	$27.53M	10.32	-$1.79M	-$0.08	N/A

In the previous week, Seer had 9 more articles in the media than Syntec Optics. MarketBeat recorded 14 mentions for Seer and 5 mentions for Syntec Optics. Syntec Optics' average media sentiment score of 0.92 beat Seer's score of 0.34 indicating that Syntec Optics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syntec Optics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seer has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Syntec Optics has a beta of -0.86, indicating that its share price is 186% less volatile than the broader market.

Seer presently has a consensus price target of $4.00, suggesting a potential upside of 103.05%. Given Seer's stronger consensus rating and higher possible upside, equities analysts clearly believe Seer is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Syntec Optics has a net margin of -10.95% compared to Seer's net margin of -464.78%. Seer's return on equity of -26.58% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-464.78%	-26.58%	-23.51%
Syntec Optics	-10.95%	-30.86%	-12.35%

Summary

Seer beats Syntec Optics on 9 of the 16 factors compared between the two stocks.

How does Seer compare to Standard BioTools?

Seer (NASDAQ:SEER) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Standard BioTools has a net margin of 73.46% compared to Seer's net margin of -464.78%. Standard BioTools' return on equity of -8.18% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-464.78%	-26.58%	-23.51%
Standard BioTools	73.46%	-8.18%	-6.43%

Seer currently has a consensus target price of $4.00, suggesting a potential upside of 103.05%. Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 62.03%. Given Seer's stronger consensus rating and higher possible upside, equities research analysts plainly believe Seer is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Seer has higher earnings, but lower revenue than Standard BioTools. Seer is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$14.68M	7.38	-$73.60M	-$1.24	N/A
Standard BioTools	$86.26M	3.77	-$74.90M	$0.20	4.17

In the previous week, Seer had 6 more articles in the media than Standard BioTools. MarketBeat recorded 14 mentions for Seer and 8 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.83 beat Seer's score of 0.34 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seer has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

75.2% of Seer shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 26.8% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Seer and Standard BioTools tied by winning 8 of the 16 factors compared between the two stocks.

How does Seer compare to Prenetics Global?

Seer (NASDAQ:SEER) and Prenetics Global (NASDAQ:PRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Prenetics Global has higher revenue and earnings than Seer. Prenetics Global is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$14.68M	7.38	-$73.60M	-$1.24	N/A
Prenetics Global	$120.07M	2.63	-$37.71M	-$4.58	N/A

Seer has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Seer currently has a consensus target price of $4.00, suggesting a potential upside of 103.05%. Prenetics Global has a consensus target price of $34.25, suggesting a potential upside of 82.76%. Given Seer's stronger consensus rating and higher probable upside, equities analysts clearly believe Seer is more favorable than Prenetics Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Prenetics Global has a net margin of -62.45% compared to Seer's net margin of -464.78%. Prenetics Global's return on equity of -20.33% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-464.78%	-26.58%	-23.51%
Prenetics Global	-62.45%	-20.33%	-15.42%

75.2% of Seer shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Seer had 9 more articles in the media than Prenetics Global. MarketBeat recorded 14 mentions for Seer and 5 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.41 beat Seer's score of 0.34 indicating that Prenetics Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prenetics Global	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Seer beats Prenetics Global on 10 of the 17 factors compared between the two stocks.

How does Seer compare to 908 Devices?

908 Devices (NASDAQ:MASS) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

908 Devices currently has a consensus price target of $12.00, indicating a potential upside of 68.07%. Seer has a consensus price target of $4.00, indicating a potential upside of 103.05%. Given Seer's stronger consensus rating and higher probable upside, analysts clearly believe Seer is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

908 Devices has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Seer has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

908 Devices has higher revenue and earnings than Seer. 908 Devices is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$57.80M	4.67	$19.49M	-$1.00	N/A
Seer	$14.68M	7.38	-$73.60M	-$1.24	N/A

908 Devices has a net margin of -62.40% compared to Seer's net margin of -464.78%. 908 Devices' return on equity of -14.03% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Seer	-464.78%	-26.58%	-23.51%

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by company insiders. Comparatively, 11.3% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Seer had 13 more articles in the media than 908 Devices. MarketBeat recorded 14 mentions for Seer and 1 mentions for 908 Devices. 908 Devices' average media sentiment score of 0.56 beat Seer's score of 0.34 indicating that 908 Devices is being referred to more favorably in the media.

Company	Overall Sentiment
908 Devices	Positive
Seer	Neutral

Summary

908 Devices beats Seer on 10 of the 17 factors compared between the two stocks.

How does Seer compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Nautilus Biotechnology has a net margin of 0.00% compared to Seer's net margin of -464.78%. Seer's return on equity of -26.58% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Seer	-464.78%	-26.58%	-23.51%

Nautilus Biotechnology currently has a consensus target price of $4.00, indicating a potential upside of 136.69%. Seer has a consensus target price of $4.00, indicating a potential upside of 103.05%. Given Nautilus Biotechnology's higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Seer had 11 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 14 mentions for Seer and 3 mentions for Nautilus Biotechnology. Seer's average media sentiment score of 0.34 beat Nautilus Biotechnology's score of 0.29 indicating that Seer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seer	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nautilus Biotechnology has higher earnings, but lower revenue than Seer. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Seer	$14.68M	7.38	-$73.60M	-$1.24	N/A

Nautilus Biotechnology has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Seer has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 11.3% of Seer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Seer beats Nautilus Biotechnology on 10 of the 16 factors compared between the two stocks.

Get Seer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEER vs. The Competition

Export

Metric	Seer	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$108.32M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.59	21.48	27.14	23.64
Price / Sales	7.38	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.43	7.88	10.28	6.07
Net Income	-$73.60M	$23.86M	$3.60B	$331.99M
7 Day Performance	-9.22%	-3.82%	-1.27%	-0.63%
1 Month Performance	13.87%	-2.61%	-0.37%	-2.00%
1 Year Performance	-10.45%	32.79%	18.30%	13.62%

Seer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEER Seer	3.352 of 5 stars	$1.97 -3.9%	$4.00 +103.0%	-9.6%	$108.32M	$14.68M	N/A	160
OPTX Syntec Optics	0.1749 of 5 stars	$8.20 -1.0%	N/A	+210.6%	$333.52M	$28.08M	N/A	3	News Coverage
LAB Standard BioTools	3.6991 of 5 stars	$0.84 -1.3%	$1.35 +61.1%	-43.3%	$331.34M	$85.33M	4.19	620	Positive News Analyst Upgrade Short Interest Decrease
PRE Prenetics Global	2.1345 of 5 stars	$21.24 +13.7%	$31.75 +49.5%	+132.5%	$315.21M	$92.39M	N/A	1	News Coverage Analyst Downgrade High Trading Volume
MASS 908 Devices	1.7957 of 5 stars	$8.16 +2.6%	$12.00 +47.1%	-3.3%	$300.62M	$56.20M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEER) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seer (SEER) Competitors

SEER vs. OPTX, LAB, PRE, MASS, and NAUT

How does Seer compare to Syntec Optics?

Summary

How does Seer compare to Standard BioTools?

Summary

How does Seer compare to Prenetics Global?

Summary

How does Seer compare to 908 Devices?

Summary

How does Seer compare to Nautilus Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEER vs. The Competition

Seer Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seer (SEER) Competitors

SEER vs. OPTX, LAB, PRE, MASS, and NAUT

How does Seer compare to Syntec Optics?

Do insiders and institutionals have more ownership in SEER or OPTX?

Which has better valuation & earnings, SEER or OPTX?

Does the media favor SEER or OPTX?

Which has more volatility and risk, SEER or OPTX?

Do analysts recommend SEER or OPTX?

Is SEER or OPTX more profitable?

Summary

How does Seer compare to Standard BioTools?

Is SEER or LAB more profitable?

Do analysts recommend SEER or LAB?

Which has preferable earnings and valuation, SEER or LAB?

Does the media refer more to SEER or LAB?

Which has more risk & volatility, SEER or LAB?

Do insiders & institutionals have more ownership in SEER or LAB?

Summary

How does Seer compare to Prenetics Global?

Which has higher earnings and valuation, SEER or PRE?

Which has more risk and volatility, SEER or PRE?

Do analysts recommend SEER or PRE?

Is SEER or PRE more profitable?

Do insiders and institutionals have more ownership in SEER or PRE?

Does the media prefer SEER or PRE?

Summary

How does Seer compare to 908 Devices?

Do analysts rate MASS or SEER?

Which has more volatility & risk, MASS or SEER?

Which has higher valuation & earnings, MASS or SEER?

Is MASS or SEER more profitable?

Do insiders & institutionals believe in MASS or SEER?

Does the media prefer MASS or SEER?

Summary

How does Seer compare to Nautilus Biotechnology?

Is NAUT or SEER more profitable?

Do analysts rate NAUT or SEER?

Does the media refer more to NAUT or SEER?

Which has higher valuation & earnings, NAUT or SEER?

Which has more volatility and risk, NAUT or SEER?

Do insiders and institutionals believe in NAUT or SEER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEER vs. The Competition

Seer Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools